ATEA PHARMACEUTICALS INC (AVIR) Stock News

USA - NASDAQ:AVIR - US04683R1068 - Common Stock

2.96 USD

-0.1 (-3.27%)

Last: 11/14/2025, 8:00:01 PM

2.96 USD

0 (0%)

After Hours: 11/14/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AVIR Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

News Image

Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update

2 days ago - By: The Motley Fool

Atea Pharma (AVIR) Earnings Call Transcript

3 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

3 days ago - By: Benzinga - Mentions: GWRS IMRX DYAI LEGN ...

Earnings Scheduled For November 12, 2025

4 days ago - By: Benzinga

Atea Pharmaceuticals Earnings Preview

8 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

8 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

10 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

10 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

24 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

24 days ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

a month ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

2 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

3 months ago - By: The Motley Fool

Atea (AVIR) Q2 Loss Narrows 8%

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

6 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

7 months ago - By: Atea Pharmaceuticals, Inc. - Mentions: COYA

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

8 months ago - By: On Behalf of The Radoff-JEC Group

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations